Current therapeutic targets for angiosarcoma primarily focus on pathways such as VEGFR1-3, mTOR, MEK, c-Myc, PD-1/PD-L1, and β-adrenergic receptors35. This evidence concerns the gene MAP2K7 and angiosarcoma.